Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biotech rising like a phoenix from the ashes of Belviq's commercial flop, rose 10.6% in November, according to data from S&P Global Market Intelligence. Despite declining revenue from an ill-fated anti-obesity drug, investors have plenty to look forward to in 2018.
Although Belviq's commercial launch has been deeply disappointing, Arena's development pipeline boasts a handful of clinical-stage drugs with enough potential to put the disaster in its rearview. Encouraging data for a pulmonary arterial hypertension in development, ralinepag, lifted the stock earlier this year.
Image source: Getty Images.
Source: Fool.com
